Biogen (BIIB) Tops Q3 EPS by 68c; Announces Corp. Restructuring; Boosts FY15 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to Biogen (BIIB) Tops Q3 EPS by 68c; Announces Corp. Restructuring; Boosts FY15 EPS Outlook
October 21, 2015 7:31 AM EDT
ASCEND Phase 3 Trial Did Not Meet Primary and Secondary Endpoints;
Natalizumab Demonstrated Statistically Significant Effect on Upper Limb
Function in Patients
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
The Phase 3 ASCEND study investigating natalizumab in the treatment of
secondary progressive multiple sclerosis (SPMS) did not achieve its
primary and secondary endpoints, Biogen
(NASDAQ: BIIB) reported today. During the study, natalizumab was... More
October 21, 2015 7:30 AM EDT
Corporate restructuring to result in an 11% workforce reduction
First patient enrolled in aducanumab Phase 3 studies for Alzheimers
disease
Company announces agreement to license Mitsubishi Tanabe Pharmas
Phase 3 ready molecule for autoimmune diseases
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Biogen Inc. (NASDAQ: BIIB) today reported third quarter 2015 results,
including revenues of $2.8 billion, an 11% increase compared to the
third quarter of 2014. Non-GAAP diluted earnings per share (EPS) for the
third quarter of 2015 were $4.48, an increase of 18% over the third
quarter of 2014. Non-GAAP... More
